iwNHL 2015: Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma - 101793

Spotlight
Video

iwNHL 2015: Ibrutinib, Bruton’s tyrosine kinase inhibitor, for non-Hodgkin lymphoma

VJHemOnc has 1040 videos Subscribe Here

Loading........
Description: At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses the currently available data on the safety and efficacy of ibrutinib, a first-in-class, oral, irreversible inhibitor of Bruton’s tyrosine kinase, for the treatment of patients with non-Hodgkin lymphoma, including mantle cell lymphoma, Waldenstrom macroglobulinemia and diffuse large B-cell lymphoma.

—————

The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve understanding and awareness of hematological malignancies.

Website: http://www.vjhemonc.com/...
Twitter: https://twitter.com/VJHemOn...
Facebook: https://www.facebook.com/vj...
LinkedIn: https://www.linkedin.com/co...
Shared By : VJHemOnc
Posted on : 11/22/15
Added : 3 years ago